Calendrier des promotions Clearside Biomedical, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. plus de détails| IPO date | 2016-06-02 |
|---|---|
| ISIN | US1850631045 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://clearsidebio.com |
| Цена ао | 1.69 |
| Changement de prix par jour: | +2.15% (0.93) |
|---|---|
| Changement de prix par semaine: | +8.91% (0.8723) |
| Changement de prix par mois: | -11.21% (1.07) |
| Changement de prix sur 3 mois: | -18.1% (1.16) |
| Changement de prix sur six mois: | -22.76% (1.23) |
| Changement de prix par an: | -18.8% (1.17) |
| Evolution du prix sur 3 ans: | -67.24% (2.9) |
| Evolution du prix sur 5 ans: | -24.6% (1.26) |
| Evolution des prix sur 10 ans: | 0% (0.95) |
| Evolution des prix depuis le début de l'année: | -12.84% (1.09) |
|
|
Sous-estimation
|
Efficacité
|
|||||||||||||||||||||||||||||||||||||
Dividendes
|
Devoir
|
Impulsion de croissance
|
|||||||||||||||||||||||||||||||||||||
| Établissements | Volume | Partager, % |
|---|---|---|
| Vanguard Group Inc | 2176316 | 2.91 |
| Carmignac Gestion | 2132744 | 2.85 |
| Blackrock Inc. | 759743 | 1.02 |
| Geode Capital Management, LLC | 490690 | 0.66 |
| Renaissance Technologies, LLC | 384689 | 0.51 |
| State Street Corporation | 193363 | 0.26 |
| Bridgeway Capital Management, Inc. | 175600 | 0.24 |
| First Manhattan Company | 175000 | 0.23 |
| Johnson & Johnson | 169629 | 0.23 |
| Morgan Stanley | 144434 | 0.19 |
| ETF | Partager, % | Rentabilité pour l'année, % | Dividendes, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.02367 | 17.09 | 1.54048 |
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
|---|---|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, CEO & Director | 836.15k | 1952 (73 année) |
| Mr. Charles A. Deignan | Chief Financial Officer | 568.68k | 1964 (61 année) |
| Ms. Jenny R. Kobin | Head of Investor Relations | N/A | 1967 (58 années) |
| Mr. Rick McElheny | Senior Vice President of Corporate Development & Alliance Management | N/A | |
| Mr. Rafael V. Andino | Senior Vice President of Engineering & Manufacturing | N/A | 1965 (60 années) |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer | N/A | |
| Mr. Leslie B. Zacks | Secretary | N/A | 1969 (56 années) |
| Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. | Chief Medical Officer |
Adresse: United States, Alpharetta. GA, 900 North Point Parkway - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://clearsidebio.com
Site web: https://clearsidebio.com
